Akers Biosciences Inc (NASDAQ:AKER)

During Friday’s Morning trade, Shares of Akers Biosciences Inc (NASDAQ:AKER), dropped – 33.88% to $1.94. The firm opened its current trade at $2.71, and as of now, it is trading at $1.94. The total volume traded for the day is 109,376.00 shares, as compared to its average daily volume of 15,191.00 shares. The stock is floating in a range of $1.76 - $3.08. The stock holds the market capitalization of $15.13M.

Akers Biosciences, Inc. (AKER) reports its earnings for the third quarter and nine months ended September 30, 2015.

Financial Highlights:

• Total Revenue for nine months ended September 30, 2015 was $1,325,887 (9M 2014: $2,980,389). The decrease resulted from there having been an initial stocking order for Tri-Cholesterol “Check” tests during the nine months ended September 30, 2014 which was not repeated in the nine months ended September 30, 2015; and from the impact on sales of BreathScan breathalyzer products following the French government’s postponement, indefinitely, of the fine that was to be imposed for drivers failing to possess breathalyzers in their vehicles
• Importantly, sales of the flagship PIFA Heparin/PF4 Rapid Assay products raised by 9% over the nine month period ended September 30, 2014
• Product Revenue for Q3 2015 was $169,473 (Q3 2014: $359,980), reflecting lower than usual distributor stock depletion of PIFA Heparin/PF4 Rapid Assay products during the summer months — demand returning to normal levels in Q4
• Loss before income tax for Q3 was $2,326,893 (Q3 2014: loss of $1,124,320), reflecting significantly expanded personnel costs, higher marketing costs associated with product launches, higher R&D costs associated with new product development and a one-off impairment ($466,476) of historic patents/trademarks no longer contributing to sales
• Cash and marketable securities at September 30, 2015 were $5,622,597 ($9,720,802 at December 31, 2014)

“Akers Bio’s product revenues in the first nine months of the year were $1,325,877. This is primarily being driven by the growth in domestic sales of our flagship rapid tests for Heparin-Induced Thrombocytopenia — an allergic reaction to the widely used blood thinner, heparin. Sales of these products are up 9% in the year to date. In fact, Akers Bio now has over 200 hospital customers in the US using these tests out of the 2,500 large hospitals we are initially targeting. Each of our PIFA Heparin/PF4 Rapid Assay hospital customers is worth an average of $15,000 to Akers Bio annually.

Akers Biosciences, Inc., together with its auxiliaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally.

Amedica Corporation (NASDAQ:AMDA)

Shares of Amedica Corporation (NASDAQ:AMDA), dipped -17.36% to $0.101, during its current trading session.

Amedica Corporation (AMDA), stated financial results for the third quarter ended September 30, 2015.

For the three months ended September 30, 2015, Amedica recorded product revenue of $4.8 million, a decrease of $1.2 million, or 19%, as contrast to the same period in 2014. The reduction was primarily due to reduced sales of non-silicon nitride products, which declined by $0.9 million, or 27%, for the third quarter as contrast to the same period in 2014. Silicon nitride sales reduced by $0.3 million, or 10%, during the quarter as contrast to the same period in 2014. This decline was primarily attributable to the loss of a few surgeons during 2015 and consequences from our restructuring. This was partially offset by the addition of new surgeons, in addition to international and private label sales.

Cost of revenue for the quarter reduced $0.3 million, or 15%, as contrast to the same period in 2014. The decrease in cost of revenue was primarily a result of reduced sales for the current year period, as contrast to the same period in 2014. Not Taking Into Account the impact of excess or obsolete inventory for both years, third quarter 2015 gross margins ended at 73% of total sales, as contrast to 82% during the preceding year period. Although product costs have been reduced through production efficiencies and lower overhead costs, the decline in gross margins was due to private label and raised international sales during the third quarter of 2015, which have lower gross margins due to lower selling prices, but have higher operating contribution margins since no commissions are paid on those sales and it requires less operating expenses to support these sales.

Operating expenses for the third quarter of 2015 declined by 38%, or $3.7 million, from the preceding year period, to $6.0 million. This year-over-year decline in operating expenses is primarily due to the actions taken by the Company to simplify the organization and align financial objectives earlier in the year, in addition to lower commission costs and a $1.7 million reduction in stock-based compensation expense during the third quarter of 2015.

Amedica stated a net loss for the third quarter of $(10.1) million, contrast to a net loss of $(4.9) million in the preceding-year period. The improvement in net loss was primarily the result of an $8.0 million improvement in the fair value of derivative liabilities, which was partially offset by reduced operating expenses of $3.7 million for the period. By December 31, 2015, the Company anticipates the majority of its derivative liabilities will be extinguished as a result of the completion of the most recent equity financing.

Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America.

Skyline Medical Inc (NASDAQ:SKLN)

Finally, Shares of Skyline Medical Inc (NASDAQ:SKLN), lower -16.84%, and is now trading at $3.95.

On November 10, Skyline Medical Inc. (SKLN) declared that as part of its international expansion strategy the Company is in the process of filing national stage patent applications for the technologies and processes applied in its flagship product, the STREAMWAY® System. The initial applications are being applied for in Canada and select European countries.

The patents cover innovative technology to allow for direct-to-drain fluid waste disposal and allows the system to provide continuous suction to the field and unlimited waste fluid capacity.

Josh Kornberg, CEO of Skyline Medical, said, “We are excited to implement these steps forward in our strategy to expand commercial activities into major international markets and establish Skyline Medical as a market leader in medical waste administration. Since entering the US market, the STREAMWAY System has proven itself to be a safer, more efficient and cost effective waste fluid administration system for medical facilities.”

Skyline Medical, Inc., a development stage medical device company, manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the United States.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.